Proteomics for Chronic Kidney Disease Therapy

Objetivo

The social and financial burden that chronic kidney disease (CKD) imposes on European countries is significant. Currently 16.95% of the global population suffers from CKD. The prevalence of the disease has increased steadily during the previous decades and it is expected to reach alarming rates in the near future. It is thus apparent that an effective treatment for CKD will have a positive social and financial impact. The pathological basis of CKD is complex and the molecular mechanisms responsible for the onset and progression of the disease have not been fully elucidated. Their elucidation will enable the identification of specific therapeutic targets. Currently there are significant -omics datasets available on CKD deposited in databases. However, a marked deficiency of these datasets is the scarcity of kidney tissue proteomics data. PROCEED targets the mapping of kidney tissue proteomics changes in association to CKD phenotypes, integration of –omics datasets with clinical data by systems biology approaches, and subsequently prediction of novel therapeutic targets. The output of the proposed study is expected to fill a very important gap in the existing knowledge in the field, namely provide the in situ comprehensive proteomics phenotyping of renal disease progression. The project is timely and in accordance with the current European research developments and societal needs. Through this project the ER who has spent most of his career in academia will be able to acquire unique skills available in the industrial setting. Upon completion of the project he is expected to return to his academic institution and act as a catalyst that will facilitate the translation of research findings to the industrial and clinical setting.